{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:57:00Z","timestamp":1785369420782,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.urolonc.2019.05.018","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T23:57:15Z","timestamp":1561593435000},"page":"5.e9-5.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer"],"prefix":"10.1016","volume":"38","author":[{"given":"Marcus J.","family":"Daniels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Schoenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Lamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8296-4115","authenticated-orcid":false,"given":"Alex","family":"Sankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2019.05.018_bib0001","first-page":"7","article-title":"Cancer Statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"Ca Cancer J Clin"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0002","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/cncr.24147","article-title":"Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000","volume":"115","author":"David","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0003","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Burger","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0004","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5489\/cuaj.1196","article-title":"The management of BCG failure in non\u2013muscle-invasive bladder cancer: an update","volume":"3","author":"Zlotta","year":"2009","journal-title":"Can Urol Assoc"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0006","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.juro.2013.08.022","article-title":"The effect of restaging transurethral resection on recurrence and progression rates in patients with non-muscle invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin","volume":"191","author":"Sfakianos","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0007","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0008","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0090-4295(97)00067-8","article-title":"Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response","volume":"49","author":"Bui","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0009","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0090-4295(99)00591-9","article-title":"Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer","volume":"55","author":"Brake","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0010","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0011","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0022-5347(17)45091-9","article-title":"Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder","volume":"136","author":"Haaff","year":"1986","journal-title":"J Urol"},{"issue":"2 Pt 1","key":"10.1016\/j.urolonc.2019.05.018_bib0012","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-5347(17)32741-6","article-title":"Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy","volume":"152","author":"Nadler","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0013","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent Ta, T1 and carcinoma in situ TCC of the bladder: a randomized SWOG study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0014","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0016","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0017","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0018","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.juro.2008.11.124","article-title":"Molecular analyte profiling of the early events and tissue conditioning following intravesical Bacillus Calmette-Guerin therapy in patients with superficial bladder cancer","volume":"181","author":"Bisiauxac","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0019","doi-asserted-by":"crossref","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/2326-6066.CIR-16-0267","article-title":"Intravesical BCG induces CD4+ T-cell expansion in an immune competent model of bladder cancer","volume":"5","author":"Kates","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0021","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.juro.2017.12.057","article-title":"Purified protein derivative skin test prior to Bacillus Calmette-Gu\u00e9rin therapy may have therapeutic impact in patients with nonmuscle invasive bladder cancer","volume":"199","author":"Niwa","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.05.018_bib0022","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2018.08.015","article-title":"Background and update for S1602 \"A phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-na\u00efve high-grade non-muscle-invasive bladder cancer","volume":"4","author":"Svatek","year":"2018","journal-title":"Eur Urol Focus."},{"key":"10.1016\/j.urolonc.2019.05.018_bib0023","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.urolonc.2016.11.016","article-title":"Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer","volume":"35","author":"Steinberg","year":"2017","journal-title":"Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919302182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919302182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:16:31Z","timestamp":1761041791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143919302182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1078143919302182"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.05.018","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}